August 2012
-
On the first day of the Inhalation Drug Symposium 2013 held November 8-9, 2013 in Nanjing, China, a group of five inhalation medicine specialists proposed the formation of a new organization to be called the… Read more . . .
-
Imperial Innovations Group has announced that it is contributing £4.25 million towards a total of £17 million ($27.5 million) in funding for a new inhaled drug discovery and development company called Pulmocide. Other investors in… Read more . . .
-
Copley Scientific has announced that it will introduce the new Child Alberta Idealised Throat for inhaler testing at Drug Delivery to the Lungs 24 along with its recently introduced TPK-R critical flow controller. The child… Read more . . .
-
Two inhalation combination products have been launched in Japan within a day of each other. Skyepharma has announced that its Japanese partner Kyorin launched a 56-inhalation version of the Flutiform fluticasone/formoterol MDI, and Sosei has… Read more . . .
-
Cornerstone Therapeutics has launched Bethkis tobramycin inhalation solution for the treatment of cystic fibrosis patients with P. aeruginosa infections in the US, the company said. According to Cornerstone, one dose of Bethkis contains 300 mg… Read more . . .
-
In accordance with their promise to provide open access to meeting materials, the organizers of Inhalation Asia 2013 have made all of the presentations from the meeting available on the meeting’s website. The presentations include… Read more . . .
-
Anyone who left the 2013 AAPS Annual Meeting after the first couple of days missed most of the highlights for OINDP specialists. . . . Read more Read more . . .
-
Aradigm has announced the appointment of Juergen Froehlich as Chief Medical Officer. Froehlich is formerly Head of Regulatory Affairs at Vertex Pharmaceuticals where he was responsible for regulatory submissions for Kalydeco. Both of Aradigm’s inhaled… Read more . . .
-
Particle Sciences has announced that it has been awarded a contract for development of an intranasal progesterone formulation for the treatment of traumatic brain injury by BHR Pharma, a subsidiary of Besins Healthcare. Besins announced… Read more . . .
-
Dutch pharmaceutical compliance specialist Timer Designs has announced the launch of the Compliance Cradle for Advair/Seretide Diskus inhalers. The device monitors the presence of the Diskus and alerts patients to take a dose of the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland